title: The kidney transplant program at the Massachusetts general hospital.
abstract: Between February 1963 and December 2000, 1,627 kidney transplants were performed at the Massachusetts General Hospital. The majority (62%) were from cadaveric donors, although in recent years (1996-2000) 52% have been allografts from living donors, with an increase in living unrelated donors. The introduction of CsA and OKT3 in 1984 was associated with a significant improvement in actuarial renal allograft survival, although a persistent late attrition of allografts continues beyond the first year after transplantation. As reported in other centers, current actuarial survival for living unrelated allografts is superior to that of cadaveric allografts, and is quite similar to that observed in recipients of non-HLA identical living-related transplants. Our preliminary laparoscopic donor nephrectomy experience is encouraging as excellent allograft survival and function has been observed, with minimal morbidity associated with the procedure and a low rate of conversion to open nephrectomy. Recent changes in immunosuppressive protocols have resulted in lower early acute rejection rates, however the incidence of delayed graft function remains unchanged in cadaveric renal transplantation. The role of humoral immunity in allograft rejection has been progressively clarified and new approaches to control donor specific alloantibody production have been shown to be effective. Current clinical studies are ongoing to determine the optimal type and dose of calcineurin inhibitors beyond the first year after transplantation and to study whether avoidance of steroids is safe and feasible. Finally, an innovative tolerance induction protocol using the mixed chimerism approach has been successfully accomplished in selected patients with end-stage renal disease secondary to multiple myeloma. These encouraging observations emphasize that major changes from current immunosuppressive regimens are likely to occur over the next few years as more approaches to tolerance induction are explored clinically.
authors.affiliation: Transplantation Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: M
authors.initials: M
authors.lastname: Pascual
authors.forename: N
authors.initials: N
authors.lastname: Tolkoff-Rubin
authors.forename: M L
authors.initials: ML
authors.lastname: Farrell
authors.forename: W
authors.initials: W
authors.lastname: Williams
authors.forename: H
authors.initials: H
authors.lastname: Auchincloss
authors.forename: D
authors.initials: D
authors.lastname: Ko
authors.forename: S
authors.initials: S
authors.lastname: Saidman
authors.forename: R B
authors.initials: RB
authors.lastname: Colvin
authors.forename: A B
authors.initials: AB
authors.lastname: Cosimi
authors.forename: F L
authors.initials: FL
authors.lastname: Delmonico
mesh_terms: D006084:Graft Rejection / Q000517:prevention & control / Q000628:therapy; D006085:Graft Survival; D006769:Hospitals, General; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology; D010535:Laparoscopy; D008404:Massachusetts; D014019:Tissue Donors; D014184:Transplantation, Homologous